| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 代理产品(元) | - | - | - | 7,679,343.73 | 6,354,644.04 |
| 鲑降钙素注射液(元) | 134,325,545.30 | 165,156,800.38 | 129,945,385.35 | 155,760,909.89 | 134,034,246.71 |
| 技术转让收入(元) | - | - | - | - | 1,886,792.45 |
| 苏灵(元) | 326,139,856.87 | - | 274,587,705.76 | - | 308,559,864.67 |
| 鲑降钙素鼻用喷雾剂(元) | - | 67,500,165.31 | - | 140,817,571.76 | - |
| 注射用尖吻蝮蛇血凝酶(元) | - | 591,771,211.49 | - | 613,495,567.85 | - |
| 营业成本(元) | |||||
| 代理产品(元) | - | - | - | 7,565,543.32 | - |
| 鲑降钙素注射液(元) | 20,406,013.52 | 21,525,097.00 | 16,186,488.15 | 20,641,896.88 | - |
| 技术转让收入(元) | - | - | - | - | - |
| 苏灵(元) | 24,474,859.89 | - | 25,779,733.73 | - | - |
| 鲑降钙素鼻用喷雾剂(元) | - | 8,478,116.48 | - | 17,704,293.70 | - |
| 注射用尖吻蝮蛇血凝酶(元) | - | 55,290,403.93 | - | 54,846,898.45 | - |
| 毛利(元) | |||||
| 代理产品(元) | - | - | - | 113,800.41 | - |
| 鲑降钙素注射液(元) | 113,919,531.78 | 143,631,703.38 | 113,758,897.20 | 135,119,013.01 | - |
| 技术转让收入(元) | - | - | - | - | - |
| 苏灵(元) | 301,664,996.98 | - | 248,807,972.03 | - | - |
| 鲑降钙素鼻用喷雾剂(元) | - | 59,022,048.83 | - | 123,113,278.06 | - |
| 注射用尖吻蝮蛇血凝酶(元) | - | 536,480,807.56 | - | 558,648,669.40 | - |
| 毛利率(%) | |||||
| 代理产品(%) | - | - | - | 1.48 | - |
| 鲑降钙素注射液(%) | 84.81 | 86.97 | 87.54 | 86.75 | - |
| 技术转让收入(%) | - | - | - | - | - |
| 苏灵(%) | 92.50 | - | 90.61 | - | - |
| 鲑降钙素鼻用喷雾剂(%) | - | 87.44 | - | 87.43 | - |
| 注射用尖吻蝮蛇血凝酶(%) | - | 90.66 | - | 91.06 | - |
| 收入构成(%) | |||||
| 代理产品(%) | - | - | - | 0.84 | 1.41 |
| 鲑降钙素注射液(%) | 29.17 | 20.03 | 32.12 | 16.97 | 29.73 |
| 技术转让收入(%) | - | - | - | - | 0.42 |
| 苏灵(%) | 70.83 | - | 67.88 | - | 68.44 |
| 鲑降钙素鼻用喷雾剂(%) | - | 8.19 | - | 15.34 | - |
| 注射用尖吻蝮蛇血凝酶(%) | - | 71.78 | - | 66.85 | - |
| 毛利构成(%) | |||||
| 代理产品(%) | - | - | - | 0.01 | - |
| 鲑降钙素注射液(%) | 27.41 | 19.43 | 31.38 | 16.54 | - |
| 技术转让收入(%) | - | - | - | - | - |
| 苏灵(%) | 72.59 | - | 68.62 | - | - |
| 鲑降钙素鼻用喷雾剂(%) | - | 7.99 | - | 15.07 | - |
| 注射用尖吻蝮蛇血凝酶(%) | - | 72.58 | - | 68.38 | - |